Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Leo Pharma publishes new data on actinic keratosis treatment

Leo Pharma publishes new data on actinic keratosis treatment

15th June 2011

Leo Pharma has published new clinical data from four studies of ingenol mebutate gel, an investigational treatment for actinic keratosis.

The company attended the recent World Congress of Dermatology in Seoul to present results from four phase III clinical trials of the drug, a topical gel derived from the Euphorbia peplus plant.

In two of the studies, the treatment proved to offer a superior performance to placebo among patients applying the gel to their faces and scalp, while the other two trials demonstrated similar levels of efficacy when used on the body.

Dr Mark Lebwohl, professor and chair of the department of dermatology at Mount Sinai Medical Center, said: "Since there is no way to predict which actinic keratoses will advance to skin cancer, early detection and treatment of lesions is critical."

Data from these studies is now being used to support Leo Pharma's efforts to seek regulatory approval for the new drug.

Leo Pharma is aiming to build on its strong recent performance in 2011, with group sales reaching a record level last year.ADNFCR-8000103-ID-800579321-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.